BioSpace News Archive

Viracta Therapeutics, Inc., a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced that the Compensation Committee of Viracta’s Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 80,000 shares of common stock.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Edward C. Dow, who joined Oncternal as Vice President, Clinical Development.

Vivani Medical, Inc. announced financial results for the third quarter ending September 30, 2022 and provides business updates.

Retractable Technologies, Inc. reports that its operating income was $7.0 million for the first nine months of 2022 and that it had an operating loss of $691 thousand for the third quarter of 2022, as compared to an operating income for the same periods last year of $44.1 million for the first nine months of 2021 and an operating income of $8.0 million for the third quarter of 2021.

ViewRay, Inc. announced that it has entered into a new five-year loan facility agreement with MidCap Financial and Silicon Valley Bank.

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share, payable on February 1, 2023 to shareholders of record of Quest Diagnostics common stock on January 18, 2023.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced its financial results for the three-month and nine-month periods ended September 30, 2022.

Todos Medical, Ltd. announced that it will host the third quarter of 2022 earnings and business update conference call on November 15th, 2022 at 8:30am ET.

Harbor BioMed announced establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND.

Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the quarter ended September 30, 2022 and provided an update on its business strategy and corporate progress.